Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 132, Issue 3
July 19 2018
Blood Cover Image for Volume 132, Issue 3

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
The cells are ambiguous, not the message Free
Clinical Trials & Observations
Pierre S. Rohrlich
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Lymphoid Neoplasia
PI3K inhibitors and the search for the Holy Grail Free
Ian W. Flinn
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
MYELOID NEOPLASIA
HSP90 inhibition without heat shock response Free
John C. Byrd
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
TRANSFUSION MEDICINE
XG blood group puzzle solved: what’s next? Free
Peter A. Zimmerman
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

REVIEW ARTICLE

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas Free
Norbert Schmitz,Georg Lenz,Matthias Stelljes
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

HOW I TREAT

How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa Free
Clinical Trials & Observations
Satish Gopal,Thomas G. Gross
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CLINICAL TRIALS AND OBSERVATIONS

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia Free
CME Clinical Trials & Observations
Ondrej Hrusak,Valerie de Haas,Jitka Stancikova,Barbora Vakrmanova,Iveta Janotova,Ester Mejstrikova,Vaclav Capek,Jan Trka,Marketa Zaliova,Ales Luks,Kirsten Bleckmann,Anja Möricke,Julie Irving,Benigna Konatkowska,Thomas B. Alexander,Hiroto Inaba,Kjeld Schmiegelow,Simone Stokley,Zuzana Zemanova,Anthony V. Moorman,Jorge Gabriel Rossi,Maria Sara Felice,Luciano Dalla-Pozza,Jessa Morales,Michael Dworzak,Barbara Buldini,Giuseppe Basso,Myriam Campbell,Maria Elena Cabrera,Neda Marinov,Sarah Elitzur,Shai Izraeli,Drorit Luria,Tamar Feuerstein,Alexandra Kolenova,Peter Svec,Olena Kreminska,Karen R. Rabin,Sophia Polychronopoulou,Elaine da Costa,Hanne Vibeke Marquart,Antonis Kattamis,Richard Ratei,Dirk Reinhardt,John K. Choi,Martin Schrappe,Jan Stary
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A Free
Brief Report
Manuel Buscarlet,Sylvie Provost,Yassamin Feroz Zada,Vincent Bourgoin,Luigina Mollica,Marie-Pierre Dubé,Lambert Busque
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Hypomorphic Rag1 mutations alter the preimmune repertoire at early stages of lymphoid development Free
L. M. Ott de Bruin,M. Bosticardo,A. Barbieri,S. G. Lin,J. H. Rowe,P. L. Poliani,K. Ching,D. Eriksson,N. Landegren,O. Kämpe,J. P. Manis,L. D. Notarangelo
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

LYMPHOID NEOPLASIA

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma Free
Clinical Trials & Observations
Tycel J. Phillips,Andres Forero-Torres,Taimur Sher,Catherine S. Diefenbach,Patrick Johnston,Moshe Talpaz,Jennifer Pulini,Li Zhou,Peggy Scherle,Xuejun Chen,Paul M. Barr
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

MYELOID NEOPLASIA

Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response Free
Sanil Bhatia,Daniela Diedrich,Benedikt Frieg,Heinz Ahlert,Stefan Stein,Bertan Bopp,Franziska Lang,Tao Zang,Tobias Kröger,Thomas Ernst,Gesine Kögler,Andreas Krieg,Steffen Lüdeke,Hana Kunkel,Ana J. Rodrigues Moita,Matthias U. Kassack,Viktoria Marquardt,Friederike V. Opitz,Marina Oldenburg,Marc Remke,Florian Babor,Manuel Grez,Andreas Hochhaus,Arndt Borkhardt,Georg Groth,Luitgard Nagel-Steger,Joachim Jose,Thomas Kurz,Holger Gohlke,Finn K. Hansen,Julia Hauer
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells Free
Yankai Zhang,Alireza Paikari,Pavel Sumazin,Carly C. Ginter Summarell,Jacy R. Crosby,Eric Boerwinkle,Mitchell J. Weiss,Vivien A. Sheehan
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

TRANSFUSION MEDICINE

Disruption of a GATA1-binding motif upstream of XG/PBDX abolishes Xga expression and resolves the Xg blood group system Free
Brief Report
Mattias Möller,Yan Quan Lee,Karina Vidovic,Sven Kjellström,Linda Björkman,Jill R. Storry,Martin L. Olsson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

LETTER TO BLOOD

Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven Free
Clinical Trials & Observations
Hugo J. A. Adams,Thomas C. Kwee
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

BLOOD WORK

Aberrant T-cell antigen expression in a plasma cell neoplasm Free
Smita Patel,Bachir Alobeid
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

ERRATUM

Table of contents. Blood. 2018;131(18):ix-x. Free
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Ambiguous lineage leukemia treatment Free
CME
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
All Issues

Advertisement intended for health care professionals

STK10 regulates platelet function in arterial thrombosis and thromboinflammation
The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials
Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?
ReXPOsing a weakness in TP53-mutant MDS and AML
Making sense of factor VIII’s breakdown

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 

Advertisement intended for health care professionals